Advanced-glycation end products in insulin-resistant states

Research output: Contribution to journalReview ArticleResearchpeer-review

24 Citations (Scopus)

Abstract

Insulin resistance is a central component of a number of clinical conditions, including the metabolic syndrome, diabetes, and hypertension. There is emerging evidence that the consequent hyperinsulinemia and visceral adiposity may be directly responsible for the excess cardiovascular morbidity and mortality seen in these conditions. Advanced-glycation end products, a chemically diverse group of compounds found in higher levels in insulin-resistant states, have also been shown to adversely affect endothelial function as well as activate numerous intracellular signaling pathways implicated in the atherosclerotic pathway. In this review, we summarize the factors thought to be important in both the initiation and exacerbation of the insulin-resistant state, and directly examine the potential role of advanced-glycation end products in this process.

Original languageEnglish
Pages (from-to)96-102
Number of pages7
JournalCurrent Hypertension Reports
Volume7
Issue number2
DOIs
Publication statusPublished - 1 Jan 2005
Externally publishedYes

Cite this

@article{aa88e2c60b944d0e8bfffe3071569abb,
title = "Advanced-glycation end products in insulin-resistant states",
abstract = "Insulin resistance is a central component of a number of clinical conditions, including the metabolic syndrome, diabetes, and hypertension. There is emerging evidence that the consequent hyperinsulinemia and visceral adiposity may be directly responsible for the excess cardiovascular morbidity and mortality seen in these conditions. Advanced-glycation end products, a chemically diverse group of compounds found in higher levels in insulin-resistant states, have also been shown to adversely affect endothelial function as well as activate numerous intracellular signaling pathways implicated in the atherosclerotic pathway. In this review, we summarize the factors thought to be important in both the initiation and exacerbation of the insulin-resistant state, and directly examine the potential role of advanced-glycation end products in this process.",
author = "Georgia Soldatos and Cooper, {Mark E.} and Jandeleit-Dahm, {Karin A.M.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/s11906-005-0081-5",
language = "English",
volume = "7",
pages = "96--102",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Springer-Verlag London Ltd.",
number = "2",

}

Advanced-glycation end products in insulin-resistant states. / Soldatos, Georgia; Cooper, Mark E.; Jandeleit-Dahm, Karin A.M.

In: Current Hypertension Reports, Vol. 7, No. 2, 01.01.2005, p. 96-102.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Advanced-glycation end products in insulin-resistant states

AU - Soldatos, Georgia

AU - Cooper, Mark E.

AU - Jandeleit-Dahm, Karin A.M.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Insulin resistance is a central component of a number of clinical conditions, including the metabolic syndrome, diabetes, and hypertension. There is emerging evidence that the consequent hyperinsulinemia and visceral adiposity may be directly responsible for the excess cardiovascular morbidity and mortality seen in these conditions. Advanced-glycation end products, a chemically diverse group of compounds found in higher levels in insulin-resistant states, have also been shown to adversely affect endothelial function as well as activate numerous intracellular signaling pathways implicated in the atherosclerotic pathway. In this review, we summarize the factors thought to be important in both the initiation and exacerbation of the insulin-resistant state, and directly examine the potential role of advanced-glycation end products in this process.

AB - Insulin resistance is a central component of a number of clinical conditions, including the metabolic syndrome, diabetes, and hypertension. There is emerging evidence that the consequent hyperinsulinemia and visceral adiposity may be directly responsible for the excess cardiovascular morbidity and mortality seen in these conditions. Advanced-glycation end products, a chemically diverse group of compounds found in higher levels in insulin-resistant states, have also been shown to adversely affect endothelial function as well as activate numerous intracellular signaling pathways implicated in the atherosclerotic pathway. In this review, we summarize the factors thought to be important in both the initiation and exacerbation of the insulin-resistant state, and directly examine the potential role of advanced-glycation end products in this process.

UR - http://www.scopus.com/inward/record.url?scp=20444372284&partnerID=8YFLogxK

U2 - 10.1007/s11906-005-0081-5

DO - 10.1007/s11906-005-0081-5

M3 - Review Article

VL - 7

SP - 96

EP - 102

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 2

ER -